J. Samra

Publications279
h-index42
Citations11,613
Highly Influential Citations467
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Gill
  • 653 Publications • 21,468 Citations
  • R. Hruban
  • 1,305 Publications • 153,138 Citations
  • elliot k fishman
  • 782 Publications • 45,526 Citations
  • C. Bassi
  • 970 Publications • 57,934 Citations
  • Publications
  • Influence
Genomic analyses identify molecular subtypes of pancreatic cancer
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S…
View on Nature
Whole genomes redefine the mutational landscape of pancreatic cancer
TLDR
Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency, and 4 of 5 individuals with these measures of defective DNA maintenance responded to platinum therapy.
View on Nature
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
TLDR
It is found that frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, are also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement ofAxon guidance genes in pancreatic carcinogenesis.
View on Springer
Whole-genome landscape of pancreatic neuroendocrine tumours
TLDR
Gene expression analyses identified a subgroup of tumours associated with hypoxia and HIF signalling and described the mutational signatures they harbour, including a deficiency in G:C > T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase.
View on Nature
Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types
TLDR
It is concluded that negative staining for SDHB is characteristic of the GISTs of CT and the subgroup of pediatric Gists which it resembles, and when negativeStaining occurs in apparently sporadic GIST's in adults, the GISMs show morphologic and clinical features similar to pediatric and CT type GISTS.
View on Wolters Kluwer
Postprandial lipemia: the origin of an early peak studied by specific dietary fatty acid intake during sequential meals.
TLDR
The hypothesis that fat from a previous meal contributes to this early postprandial lipemia is tested by investigating the effect of consuming a lunch containing 61 g fat 5 h after a breakfast containing 54 g fat.
View on PubMed
The prognostic and predictive value of serum CA19.9 in pancreatic cancer
TLDR
Perioperative serum CA 19.9 measurements are informative in patients with detectable CA19.9 and have potential clinical utility in predicting outcome and response to adjuvant chemotherapy.
View PDF
Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression
TLDR
It is concluded that IGF1R overexpression is a feature of succinate dehydrogenase deficient GIST as a group, rather than pediatric or wild-type GIST per se, and IGF 1R inhibition represents a potential rational therapeutic approach in this recently recognized subgroup of GIST.
View on Nature
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
TLDR
A grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter that permits the capturing of the complexity of dual radiotracer imaging in asingle parameter.
View PDF
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
TLDR
Documenting the feasibility of acquiring and screening biospecimens for actionable molecular targets in real time will aid other groups embarking on similar trials, and include the need to better prescreen patients, screen more patients, and offer more attractive clinical trial options.
View on Publisher
...
...